BREAKING NEWS: Aitia will collaborate with Orion Corporation to uncover novel drug targets and develop new therapies to fight cancer. As part of the collaboration, Aitia will utilize Orion’s pre-clinical and clinical data to build Gemini Digital Twin models that will help answer translational questions and validate unique approaches across multiple indications. This collaboration represents a fusion of Aitia's advanced AI capabilities with Orion's expertise in oncology research and development. Cancer is a global health issue, impacting millions of people, and new cases are expected to rise significantly, driven by population growth and aging. By working together, Aitia and Orion aim to unlock deeper insights into the complex biology of cancer, ultimately accelerating the development of novel therapies that could significantly improve patient outcomes. Read more about this collaboration in our press release: https://lnkd.in/gXh2AYuD #AI #DIGITALTWINS #ONCOLOGY #INNOVATION
Aitia
Biotechnology Research
Somerville, Massachusetts 5,811 followers
Leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs
About us
Aitia is the leader in the development and application of Causal AI and Digital Twins to discover the next generation of therapies for neurodegenerative diseases and Oncology. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden circuitry of human biology to identify novel targets driving disease and focused patient recruitment for clinical development. Aitia has translated those insights into its Gemini Digital Twins (computational representations of disease), which the company is using to discover new breakthrough therapies.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Somerville, Massachusetts
- Type
- Privately Held
- Founded
- 2000
- Specialties
- Data Analytics, Bioinformatics, Genomics Data, Big Data, Causal AI, Drug Discovery, Virtual Patient, In silico trials, Clinical Trial, Virtual Patient, Drug Discovery, Target Discovery, multi-omic patient data, oncology, neurodegenerative disorders, Gemini Digital Twins, Digital Twins, Gemini, and Generative AI
Locations
-
Primary
561 Windsor St
Somerville, Massachusetts 02143, US
Employees at Aitia
Updates
-
In the rapidly evolving landscape of AI in drug development, how can we distinguish between hype and genuine innovation? Our CEO Colin Hill will discuss this issue today at Biotech Alchemy’s 2024 Life Sciences Summit. Colin will be joined by a panel of experts including Mark Silverman, Director, Digital Lab and Omnichannel Strategy, Gastroenterology, AbbVie, Paul Buckman, Director, Online Media, FDA and Bob Pearson, Chair, The Next Solutions Group. The panel will explore: · What are the real-world applications of AI in drug discovery today? · How is AI reshaping workflows in biotech and pharmaceutical research? · Where do we need to focus our efforts to maximize AI's potential in healthcare? Don’t miss this event! Panel: "The Role of AI in Biotech & Healthcare: Distinguishing Hype From Innovation" Date: Sept. 26, 9:50 a.m. - 10:45 a.m. EST Agenda: https://lnkd.in/e54kj2pF
-
Don't miss The Pistoia Alliance webinar on digital twins in pharma R&D tomorrow, Sept. 19 at 10 am ET. Learn how this technology enables more informed decisions and accelerates breakthrough drug development. Featuring Bruce Church, PhD, our Chief Mathematics Officer and EVP, Research and Early Development, alongside Julia Schueler from Charles River Laboratories. Sign up here: https://lnkd.in/g7Sna8YJ #DigitalTwins #DrugDevelopment #AI #Pharma
-
Thank you to everyone who joined us today at BioCentury Inc.'s Grand Rounds event, where our CEO Colin Hill discussed "Methods-for-purpose: Analytical tools that parse signal from noise, without flattening complexity." For additional insights into how Aitia is using Causal AI and Digital Twins to accelerate drug development, read this recent article in Genetic Engineering & Biotechnology News: https://bit.ly/3ZgrEhy And be sure to catch Bruce Church, our Chief Mathematics Officer and EVP, Research and Early Development, speaking next week at the Pistoia Alliance webinar on digital twins in pharmaceutical R&D on Sept. 19 at 10 am ET along with experts from Servier and Charles River Laboratories. Sign up here: https://lnkd.in/g7Sna8YJ #AI #Biotech #DigitalTwins #CausalAI #Pharma
-
Join us and Pistoia Alliance on Sept. 19 at 10am ET for a webinar on "Digital Twins: Accelerating Drug Development and Enhancing Patient Outcomes." Our Chief Mathematics Officer and EVP, Research and Early Development, Bruce Church, PhD, will join experts including Julia Schueler from Charles River Laboratories to explore how this technology is revolutionizing pharmaceutical R&D. Register now: https://lnkd.in/g7Sna8YJ #DigitalTwins #DrugDiscovery #AI #Biotech #Pharma
-
For a real-world example how Digital Twins are being used in drug discovery, we integrate multi-omic data to create comprehensive models of disease mechanisms. This allows us to test thousands of hypotheses digitally, accelerating drug discovery and reducing costs. Using this approach, we have identified a new drug target for Huntington’s disease, and early testing has shown promising results in preclinical experiments. You can read more about our technology and science here: https://lnkd.in/gmM8dQW4 #DigitalTwins #AI #causalAI #Huntingtons #Biotech #DrugDiscovery
The computer models can act as virtual crystal balls, allowing people to peer into the future, spot problems before they materialise and test wild ideas https://econ.st/3z6FZlR Illustration: Travis Constantine
-
Next week, join our CEO Colin Hill at BioCentury Inc.'s Grand Rounds event, where he will be discussing "Methods-for-purpose: Analytical tools that parse signal from noise, without flattening complexity," on Sept. 11 at the Four Seasons Hotel, Nashville, TN. Learn more here: https://lnkd.in/gakuvuEn This panel will be moderated by Karen Tkach Tuzman, PhD, Director of Biopharma Intelligence at BioCentury Inc. and include fellow panelists: • Daniel Burkhardt, PhD, Head of Machine Learning Research, Cellarity • Wei-Qi Wei, MD, PhD, Associate Professor, Dept. of Biomedical Informatics, Vanderbilt University Medical Center #AI #Biotech #DigitalTwins #CausalAI
-
How can we effectively extract actionable insights from vast biomedical data lakes? Join our CEO Colin Hill at the BioCentury Grand Rounds panel "Methods-for-purpose: Analytical tools that parse signal from noise, without flattening complexity" to explore this crucial question on Sept. 11 at the Four Seasons Hotel, Nashville, TN. Learn more here: https://lnkd.in/gakuvuEn This panel will be moderated by Karen Tkach Tuzman, PhD, Director of Biopharma Intelligence at BioCentury Inc. and include fellow panelists: • Daniel Burkhardt, PhD, Head of Machine Learning Research, Cellarity • Wei-Qi Wei, MD, PhD, Associate Professor, Dept. of Biomedical Informatics, Vanderbilt University Medical Center #AI #Biotech #DigitalTwins #CausalAI
-
We are at a tipping point where computational power, genetic sequencing and causal AI are converging. Aitia uses these technologies to uncover hidden genetic circuits and develop effective treatments for rare diseases. Read more here: https://lnkd.in/gpGvH8vr #AI #FutureOfMedicine #HealthcareInnovation #Biotech #DigitalTwins
-
Causal AI and Digital Twins are set to revolutionize the biopharma industry by identifying novel drug targets more efficiently and accurately. This technology has the potential to significantly reduce the high failure rate in drug development. Discover how we are using this technology to identify effective treatments across a range of conditions, including Huntington's disease: https://lnkd.in/gpGvH8vr #AI #DigitalTwins #CausalAI #DrugDiscovery #Biotech #Pharma #Huntingtons